Skip to content
Peptigraph home
Shop Peptides50% off*

Is retatrutide a peptide?

Yes. Trial reports describe retatrutide as one peptide molecule that activates three receptors: GIP, GLP-1 and glucagon.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Yes. Trial reports describe retatrutide as one peptide molecule that activates three receptors: GIP, GLP-1 and glucagon.[1]

A systematic review of obesity trials also calls it a triple agonist peptide aimed at the glucagon, GIP and GLP-1 receptors.[2]

What kind of peptide it is

A later review describes it as an injectable peptide that was still in clinical trials when it was written.[3]

A review of body-composition effects puts retatrutide in the same incretin peptide family as semaglutide and tirzepatide, with glucagon-receptor activity as the extra feature.[4]

A laboratory mass-spectrometry paper lists retatrutide among nine peptide-based drugs that its method measures together.[5]

A paper on unregulated injectables names retatrutide among investigational substances that lack established human safety profiles.[6]

Common questions

What did retatrutide do in animal studies?

In obese mice, giving the peptide lowered body weight and improved blood-sugar control; this is animal data, not a human result.[7]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

How it worksTarget, mechanism and how long it acts, from the label or studies.Retatrutide overview

Sources

  1. 1Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
  2. 2Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.Journal of basic and clinical physiology and pharmacology · 2025PMID 40728138Accessed 2 Oct 2026
  3. 3The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.Pharmacological research · 2026PMID 42556625Accessed 2 Oct 2026
  4. 4Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?Diabetes care · 2024PMID 38687506Accessed 2 Oct 2026
  5. 5Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.Journal of chromatography. A · 2026PMID 42603384Accessed 2 Oct 2026
  6. 6Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.Missouri medicine · 2026PMID 42757290Accessed 2 Oct 2026
  7. 7LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.Cell metabolism · 2022PMID 35985340Accessed 2 Oct 2026

Found an error? Report a correction.